

C21orf59 siRNA (h): sc-91375

BACKGROUND

The smallest of the human chromosomes, 21 makes up about 1.5% of the human genome. Chromosome 21 contains nearly 300 genes and 47 million base pairs. Down syndrome, also known as trisomy 21, is the disease most commonly associated with chromosome 21. Alzheimer's disease, Jervell and Lange-Nielsen syndrome and amyotrophic lateral sclerosis are also associated with chromosome 21. Translocations are found to occur between chromosome 21 and 8, and chromosome 21 and 12, in certain leukemias. C21orf59, also known as C21orf48, is a 290 amino acid protein and its gene product has been provisionally designated C21orf59 pending further characterization.

REFERENCES

1. Tesson, F., et al. 1996. Exclusion of KCNE1 (IsK) as a candidate gene for Jervell and Lange-Nielsen syndrome. *J. Mol. Cell. Cardiol.* 28: 2051-2055.
2. Tyson, J., et al. 1997. IsK and KvLQT1: mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. *Hum. Mol. Genet.* 6: 2179-2185.
3. Müller, S., et al. 2000. Molecular cytogenetic dissection of human chromosomes 3 and 21 evolution. *Proc. Natl. Acad. Sci. USA* 97: 206-211.
4. Mao, R., et al. 2005. Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. *Genome Biol.* 6: R107.
5. Robakis, N.K. 2006. The discovery and mapping to chromosome 21 of the Alzheimer's amyloid gene: history revised. *J. Alzheimers Dis.* 10: 453-455.
6. Sun, X., et al. 2006. BACE2, as a novel APP θ -secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. *FASEB J.* 20: 1369-1376.
7. Ait Yahya-Graison, E., et al. 2007. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. *Am. J. Hum. Genet.* 81: 475-491.
8. Peterson, L.F., et al. 2007. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. *Blood* 110: 799-805.

CHROMOSOMAL LOCATION

Genetic locus: C21orf59 (human) mapping to 21q22.11.

PRODUCT

C21orf59 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see C21orf59 shRNA Plasmid (h): sc-91375-SH and C21orf59 shRNA (h) Lentiviral Particles: sc-91375-V as alternate gene silencing products.

For independent verification of C21orf59 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-91375A, sc-91375B and sc-91375C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

C21orf59 siRNA (h) is recommended for the inhibition of C21orf59 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

C21orf59 (B-1): sc-365792 is recommended as a control antibody for monitoring of C21orf59 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker[™] Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor C21orf59 gene expression knockdown using RT-PCR Primer: C21orf59 (h)-PR: sc-91375-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.